Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Jul 8:23:3318-3323.
doi: 10.12659/msm.902077.

Aberrant Promoter Methylation of PCDH17 (Protocadherin 17) in Serum and its Clinical Significance in Renal Cell Carcinoma

Ying-Li Lin  1   2 , Yun-Peng Wang  1 , Hong-Zhao Li  1 , Xu Zhang  1
Affiliations

Aberrant Promoter Methylation of PCDH17 (Protocadherin 17) in Serum and its Clinical Significance in Renal Cell Carcinoma

Ying-Li Lin et al. Med Sci Monit. .

Abstract

BACKGROUND Current studies indicated that PCDH17 functions as a tumor suppressor, which is frequently inactivated by aberrant promoter methylation in urologic tumors. The main purpose of this study was to investigate the methylation status of PCDH17 in serum and its clinical significance in renal cell carcinoma (RCC). MATERIAL AND METHODS The methylation status of PCDH17 in serum samples of 142 RCC patients and 34 controls was evaluated by methylation-specific PCR (MSP). Then we correlated PCDH17 methylation status with the clinicopathologic features of RCC patients and patient outcomes. RESULTS We found that PCDH17 was more frequently methylated in RCC patients than in controls. Moreover, PCDH17 methylation in serum was significantly correlated with advanced stage (p=0.044), higher grade (p=0.019), lymph node metastasis (p=0.008) and tumor progression (p<0.001). In addition, patients with methylated PCDH17 had shorter progression-free survival (p<0.001) and overall survival (p=0.017) than patients without, and PCDH17 methylation in serum was an independent prognostic factor for worse progression-free survival (HR: 4.215, 95% CI: 1.376-9.032, p<0.001) and overall survival (HR: 5.092, 95% CI: 1.149-12.357, p=0.046) of patients with RCC. CONCLUSIONS The present study indicates that PCDH17 methylation in serum is a frequent event in RCC and associated with risk factors of poor outcomes. Moreover, PCDH17 methylation in serum is a potential prognostic biomarker for patients with RCC after surgery.

PubMed Disclaimer

Conflict of interest statement

Competing of interests

The authors had no conflicts of interest to declare in relation to this article.

Figures

Figure 1
Figure 1
Representative MSP results of PCDH17 methylation in serum samples of ccRCC cases. A – Methylation positive control; B – unmethylation positive control; C – water. Case 7, 8, and 10 represented PCDH17 methylation. Case 9 and 11 represented PCDH17 unmethylation.
Figure 2
Figure 2
Patients with PCDH17 methylated showed significantly shorter progression-free survival than those without (log-rank test, p<0.001).
Figure 3
Figure 3
Patients with PCDH17 methylated showed significantly shorter overall survival than those without (log-rank test, p=0.017).
See this image and copyright information in PMC

References

    1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. Cancer J Clin. 2015;65(1):5–29. - PubMed
    1. Low G, Huang G, Fu W, et al. Review of renal cell carcinoma and its common subtypes in radiology. World J Radiol. 2016;8(5):484–500. - PMC - PubMed
    1. Capitanio U, Montorsi F. Renal cancer. Lancet. 2016;387(10021):894–906. - PubMed
    1. Breault JE, Shiina H, Igawa M, et al. Methylation of the gamma-catenin gene is associated with poor prognosis of renal cell carcinoma. Clin Cancer Res. 2005;11(2 Pt 1):557–64. - PubMed
    1. Gu L, Ma X, Wang L, et al. Prognostic value of a systemic inflammatory response index in metastatic renal cell carcinoma andconstruction of a predictive model. Oncotarget. 2016 [Epub ahead of print] - PMC - PubMed